This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $501,450 to The Washington University to conduct research on regulating tendon repair using stem cell-derived extracellular vesicles. The study aims to identify the specific subpopulation and active cargo molecules of extracellular vesicles that can enhance tendon healing and avoid...
This federal Project Grant award, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will establish a new "joint-on-chip" microphysiological system to study arthritic diseases and evaluate treatment candidates. The $618,629 award to the University of Colorado will optimize human-derived biomaterial inks for 3D bioprinting, develop a functional...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $172,700 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to the University of California, Irvine. The project aims to develop a novel therapeutic approach for improving angiogenesis (blood vessel growth) during wound healing by delivering apoptotic (dying) neutrophils within a degradable hydrogel scaffold. This is expected to stimulate an immune response in...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $626,879 in funding to the University of Southern California (USC) to conduct research into the cellular and molecular mechanisms that enable large-scale bone regeneration. The research aims to unravel the intricate processes governing the initiation and coordination of bone repair...
This $177,872 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to study the interactions between human induced pluripotent stem cell (hiPSC)-derived endothelial cells (ECs) and skeletal muscle progenitor cells (MPCs) both in vitro and in vivo. The key objectives are to: Investigate the paracrine effects of hiPSC-ECs on the...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to develop injectable alginate hydrogels containing peptides that mimic insulin-like growth factor 1 (IGF-1) and promote cell adhesion. The goal is to enhance the therapeutic potential of mesenchymal stem cells (MSCs) for intervertebral disc (IVD) repair. The $752,620 award, spanning...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $456,808 Project Grant (R21AR084303) to the Buck Institute for Research on Aging to develop innovative mass spectrometry imaging (MSI) technologies and advanced proteomic profiling capabilities to spatially visualize molecular changes in musculoskeletal tissues, particularly bones and cartilage, related to osteoarthritis, age-related changes, and injury. The project aims to employ state-of-the-art MSI and...
This federal Project Grant award, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research into the role of extracellular vesicles in mediating communication between endothelial cells and fibroblasts in skin wound healing. The $257,310 award to the University of Illinois aims to examine how endothelial cell-derived extracellular vesicles influence the...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $649,391 Project Grant (R01AR083822) to The Johns Hopkins University to research the inhibition of pathways that restrain healing after injury to epithelial tissues like skin and gut. The goal is to define the mechanism of this healing restraint in order to develop new therapies that can enhance regeneration and improve healing from diverse injuries. The 5-year grant, running from May 2025 to February...
This Project Grant award, valued at $483,070.00, was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award supports research to investigate the dynamic mechanisms of bone extracellular matrix (ECM) assembly and resorption, and how these processes are integrated with osteogenic cellular dynamics and differentiation. Key aims include using advanced live-cell...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $220,224 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to The Regents of the University of Colorado (CU) to develop "Granular Hydrogels for the Controlled Delivery of Immunomodulatory and Angiogenic Extracellular Vesicles to Enhance Bone Tissue Regeneration." This 3-year project, with a period of performance from Jul 4, 2024 to Aug 31, 2027, aims to create advanced biomaterial hydrogels capable of delivering therapeutic extracellular vesicles to promote bone tissue regeneration. The research will investigate the use of these granular hydrogels to control the release of immunomodulatory and angiogenic extracellular vesicles, which have the potential to enhance bone healing and regeneration for patients with musculoskeletal conditions.